Virgolini I, Angelberger P, Banyai M, Knöbl P, Pantev T, Neuhold N, Prager R, Sinzinger H
Department of Nuclear Medicine, University of Vienna.
Wien Klin Wochenschr. 1991;103(21):657-60.
Insulin was radioiodinated with 123I (123I-tyrosine-(A14)-insulin) to a specific activity of 1 micrograms/mCi, corresponding to 0.025 I.U. of insulin/mCi. This preparation was used for in vitro binding experiments with adipose tissue, showing active binding to the two subunits of the known insulin receptor. In a preliminary clinical investigation, 5 adipose patients with (n = 2) and without (n = 3) diabetes mellitus Type II, were subject to in vivo injection of the same radiolabeled product using 3 mCi/patient. During the first minutes of dynamic imaging, the liver was the major organ of tracer uptake in all patients. Furthermore, the pancreas, and in one patient the kidneys, were visualised. Further studies on insulin in vivo kinetics and quantification are under way.
胰岛素用123I进行放射性碘化（123I - 酪氨酸 - （A14） - 胰岛素），比活度为1微克/毫居里，相当于0.025国际单位胰岛素/毫居里。该制剂用于与脂肪组织进行体外结合实验，显示出与已知胰岛素受体的两个亚基有活性结合。在一项初步临床研究中，5名肥胖患者，其中2名患有II型糖尿病，3名未患II型糖尿病，接受了相同放射性标记产物的体内注射，剂量为3毫居里/患者。在动态成像的最初几分钟内，肝脏是所有患者中摄取示踪剂的主要器官。此外，胰腺以及一名患者的肾脏也被显影。关于胰岛素体内动力学和定量的进一步研究正在进行中。
